ALSTON & BIRD LLP for NOVO NORDISK INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 22, 2013 | $60,000 | Replaced |
| 2nd Quarter - Amendment | Mar 22, 2017 | $60,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
H.R. 8, American Taxpayer Relief Act (R&D tax credit) of 2012.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK RAYDER | — |
Pharmacy PHA
H.R.1919 Safeguarding America's Pharmaceuticals Act of 2013 and S.959 Pharmaceutical Compounding Quality and Accountability Act (for track and trace supply chain provisions).
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK RAYDER | — |
Health Issues HCR
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes), H.R. 1074 and S 539 National Diabetes Clinical Care Commission Act of 2013;H.R. 8 American Taxpayer Relief Act (Special Diabetes Program reauthorization); H.R. 1915 and S. 907 Gestational Diabetes Act of 2013; and S. 351 Protecting Seniors' Access to Medicare Act of 2013 (IPAB repeal).
| Lobbyist | Covered position, as disclosed |
|---|---|
| PETER FISE | — |
| JOYCE E GRESKO | — |
| ELINOR HILLER | — |
| MARK RAYDER | — |
| REGINA MARIA SHERICK | — |
| ROBERT SIGGINS | — |
| MARILYN K YAGER | — |
Medicare/Medicaid MMM
H.R. 962 and S. 452 Medicare Diabetes Prevention Act of 2013; Issues related to Medicare Part D and Medicaid rebates as contained in P.L. 112-25 Budget Control Act of 2011 and H.R. 8 American Taxpayer Relief Act of 2012; H.R. 1588 & S. 740 Medicare Drug Savings Act of 2013; H.R. 962 and S. 452 Medicare Diabetes Prevention Act of 2013; H.R. 1257 Preventing Diabetes in Medicare Act of 2013 and prediabetes generally;H.R. 1274 Access to Quality Diabetes Education Act of 2013 (Diabetes Self-Management Training in Medicare); Medicare diabetes screening generally.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PETER FISE | — |
| JOYCE E GRESKO | — |
| ELINOR HILLER | — |
| MARK RAYDER | — |
| REGINA MARIA SHERICK | — |
| ROBERT SIGGINS | — |
| MARILYN K YAGER | — |
Budget/Appropriations BUD
Issues related to Medicare Part D, FDA and patents in S. Con. Res. 8; FY14 Senate Budget Resolution; H Con Res. 25 House Budget Resolution; H.R. 2633 The Preventative Health Savings Act of 2013 (Modernizing cost estimates with respect to CBO scoring preventive health legislation); National Diabetes Prevention Program; HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013; FY14 Labor/HHS/Education Appropriations (National Diabetes Prevention Program).
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK RAYDER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.